New results from a clinical trial that is testing a vector vaccine MVA85A on HIV-exposed children (born to HIV-positive mothers) show that the vaccine is not only safe on new-born babies, but it also induced an immune response and did not interfere with immunogenicity of subsequent BCG vaccination.
The study tested a new concept, in which MVA85A was used as a prime vaccine while the traditional TB vaccine, BCG was used as a boost.
While BCG is a live mycobacterial vaccine that carries a safety risk for infants with immune-suppression such as HIV infection, researchers hope that a viral vectored MVA85A would avoid this potential risk.
This study tested a new concept, in which the candidate vaccine (MVA85A) was administered first as a prime at birth, followed by a BCG as a boost.
Dr Elise Nemes, a lead researcher and senior scientist at UCT’s South African Tuberculosis Vaccine Initiative (SATVI), said even though the TB vaccine research has gained momentum in recent years, there were still major obstacles.
“We found that MVA85A was safe and induced an early modest immune response that did not interfere with, or enhance an immune response induced by a subsequent BCG vaccination. This study tested for safety and immunogenicity only, a larger study would be required to test for protection against TB.”
The new vaccine has not been without controversy though.
Early this year an editorial in the British Medical Journal (BMJ) raised questions about the use of the vaccine on infants, claiming that the vaccine was linked to the deaths of monkeys.
The journal alleged that scientists who tested the vaccine on 1400 babies in Worcester between 2009 and 2011 failed to communicate the information to participants that five out of six macaque monkeys given the MVA85A vaccine at a UK lab died prematurely.
But South African scientists have refuted this information.
Professor Mark Hatherill, the director of SATVI, who was also part of the Worcester study, said the trial of 1400 infants showed that MVA85A was safe in HIV-unexposed infants.
The latest study also showed that MVA85A was safe in HIV-exposed infants.
“MVA85A vaccine has a large body of safety data from clinical trials in humans, including infants and HIV infected people. MVA85A was selected for use in this study because the vaccine had the largest body of safety data for vaccines of this type,” he said.
Hatherill said the latest study - which was done in conjunction with Stellenbosch University’s Desmond Tutu TB Centre and Oxford University - didn’t test the efficacy of the candidate vaccine against TB, but showed proof of concept that viral-vectored vaccines could be safely used and produce an immune response when used before BCG.
The question of whether that strategy can provide additional protection against TB disease would still have to be tested in both HIV exposed and unexposed infants. Globally, TB remains one of the biggest challenges facing public healthcare systems in low-and-middle-income countries.
About 1.7 million people around the globe die due to TB each year, while in South Africa more than 33 000 die from TB every year.
South Africa is one of the countries worst affected by the killer disease with the World Health Organisation (WHO) having estimated TB incidence here to be at 454 000 in 2015.
That means 0.8% of the population develops active TB every year. Almost 60% of those infected with TB are also HIV-positive. The WHO estimated 19000 cases of drug-resistant TB in South Africa, up from 7350 in 2007.
Researchers argue that while anyone can be infected with TB, but children born to HIV positive mothers are at an increased risk, including those who remain HIV negative.
Hatherill said the latest results show that giving a viral-vectored vaccine at birth, followed by BCG is a safe and feasible strategy for testing new viral-vectored and possibly subunit vaccines.
“It is likely that future vaccines to be tested in this strategy would be selected based on demonstration of protection in HIV unexposed infants,” he said.